Follow on Google News News By Tag * Companion Diagnostics * Cancer Drug Combinations * Cancer Drugs * Cancer Therapy * Cancer Targets * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Eli Lilly to present at Oncology Partnering Meeting – Feb 27-28, 2012, Las VegasJohn Herrmann, Senior Director, Global External R&D, Oncology at Eli Lilly to give a Featured Presentation at the Oncology Partnering and Deal-making Conference (February 27-28, 2012 in Las Vegas, NV)
By: GTC Conference Partnering with Lilly Oncology: Bring Proof-of-Relevance or Go Lean-to-POC Presentation will provide the audience with insight into some of the thinking that larger companies, like LILLY apply when they evaluate partnering opportunities, particularly those innovating pre-clinical to early clinic stage assets. • Risk assessment by LILLY oncology. Will highlight why proof-of-relevance is becoming increasingly important as a new threshold for partnering in an increasingly payer constrained environment • Lilly’s evolving R&D model. Will highlight what Lilly is doing to open alternative financing (“Mirror funds” and development channels to remain open to early stage innovation (including “parked” assets) that is conceptually higher risk than Lilly’s typical tolerance o What sort of assets are we looking for o What’s in it for the innovator(s) o What’s in it for the fund management o What’s in it for Lilly John Herrmann received his Ph.D. from The University of Texas M.D. Anderson Cancer Center with a research focus on mechanisms of tumor metastasis and ways to overcome mutli-drug resistance conferred by members of the Bcl-2 family. This work lead to focus on the Ubiquitin-proteasome pathway as a new intervention point and ultimately to a collaboration with Proscript/Leukocyte/ The Oncology Partnering & Deal Making Conference is a partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant issues in Oncology and partnerships that will affect the industry. This event also provides a unique venue for attendees to learn about Oncology business development trends, market, and novel technologies that shape up the industry. The top companies and experts in the Oncology field will come together to discuss the latest discoveries, technologies and partnership opportunities from their organization. Companies include Array Biopharma, A&G Pharmaceutical, Amgen, Astellas Pharma, Aveo ¬¬¬¬¬¬Pharmaceuticals, Boehringer Ingelheim, Eisai , Eli Lilly, Endocyte, Epizyme, Epic Sciences, Micromet, Novartis, OncoMed, Pfizer , Plexxikon , Pullan Consulting, QIAGEN, SAIC-Frederick, Seattle Genetics, Third Rock Ventures, YM Biosciences, and many more! The conference is part of the Targets and Strategies in Drug Discovery Summit, which consists of 4 tracks including the 2nd Ubiquitin Research and Drug Discovery , 4th Ocular Diseases & Drug Discovery , and 3rd Cancer Targets and Therapeutics Conference. For more information, please visit www.gtcbio.com # # # GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community. GTC (Global Technology Community), LLC, is a privately held company founded in 2002. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|